Results 81 to 90 of about 5,687 (195)

Acalabrutinib Approved for MCL [PDF]

Cancer Discovery, 2018
Abstract The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.
openaire   +2 more sources

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Overweight and obesity are increasing rapidly in most countries. Underweight body mass index (BMI), though much less common, is also associated with adverse health outcomes. There is poor understanding of the implications of BMI in lymphoma patients.
Serif Sungur, Yao Yao, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Tasneem Rizvi, Eliza A. Hawkes, Zoe K. McQuilten, Erica M. Wood, Nada Hamad, Tasman Armytage, Anna M. Johnston   +14 more
wiley   +1 more source

Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy

Фармакоэкономика
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and ...
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Patient Preference and Adherence, 2023
Xiaoxiao Lu,1 Bruno Emond,2 Laura Morrison,2 Frederic Kinkead,2 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2 Wasiulla Khan,1 Linda H Wu,1 Zaina P Qureshi,1 Ryan Jacobs3 1Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA,
Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R   +9 more
doaj  

Evidence and Equity Gaps in Clinical Care of Chronic Lymphocytic Leukaemia in Portugal: A Real‐World, Multicentre, Cohort Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Targeted therapies have markedly improved outcomes in chronic lymphocytic leukaemia (CLL), particularly among patients with TP53 alterations and unmutated IGHV. However, real‐world studies report persistent inequalities in access to optimal care.
Susana Esteves, Inês Coelho, José Carda, Sara Duarte, Inês Carvalhais, Daniela Alves, Rita Coutinho, Maria Gomes da Silva   +7 more
wiley   +1 more source

Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Tyrosine kinase inhibitors (TKIs) are essential in treating chronic myeloid leukaemia (CML) and other malignancies. Their absorption, however, is highly pH‐dependent, making them susceptible to interactions with acid‐suppressing agents such as proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs) and antacids ...
Marek Lapka, Anna Khryakova, Anastasiia Nazmutdinova, Chrysostomos Charalambous, Jan Bosak, Jiri Sliva   +5 more
wiley   +1 more source

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network

Pharmacology Research & Perspectives
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults, characterized by the accumulation of dysfunctional lymphocytes. Ibrutinib, a first‐generation Bruton tyrosine kinase (BTK) inhibitor, has significantly improved CLL ...
Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Catrin Tudur Smith, Gregory Y. H. Lip, Andrew R. Pettitt   +6 more
doaj   +1 more source

Identifying Risk Factors for Anxiety and Depression in Patients with Chronic Lymphocytic Leukemia [PDF]

, 2018
Pelatonia Fellowship Program AwardThe American Society of Clinical Oncology (ASCO) has provided risk factors (past psychiatric history, gender, low SES, additional chronic illness, and martial status) for greater anxiety (GAD-7) and depressive (PHQ-9 ...
Robbertz, Abigail
core  

Systematic Proteomic Characterization of EV‐A71‐Infected Mice Identifies Dynamic Molecular Changes and Therapeutic Targets

MedComm, Volume 7, Issue 4, April 2026.
Time‐resolved multi‐omics of EV‐A71‐infected BALB/c mice uncovered dynamic host responses, revealing rapid neutrophil extracellular traps (NETs) activation as a key event. Screened drugs (kinase inhibitors) suppressed viral replication in vitro and in vivo, suggesting the promise of targeting host phosphorylation networks as a viable antiviral strategy.
Wanjun Peng, Qiaochu Wang, Binbin Zhao, Lihong Zhang, Jing Wu, Xiaohui Wei, Na Rong, Zhaohua Wang, Kaihui Liu, Jiangfeng Liu, Juntao Yang, Jiangning Liu   +11 more
wiley   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core